The role and efficacy of Nintedanib

Nintedanib (Nintedanib) is a tyrosine kinase inhibitor that is effective in slowing the progression of idiopathic pulmonary fibrosis (IPF) and has an acceptable tolerability profile. Idiopathic pulmonary fibrosis is a fatal, progressive fibrotic interstitial pneumonia with limited treatment options.

Nintedanib inhibits vascular endothelial growth factor receptors 1–3, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors 1–3, which are involved in the pathogenesis of idiopathic pulmonary fibrosis. Data from the extension trial showed that nintedanib continued to slow disease progression for up to 3 years and was equally effective in patients with mild and severe lung impairment. Nintedanib treatment reduces the risk of exacerbations, and a comprehensive analysis of nintedanib clinical trial data shows a downward trend in mortality. Nintedanib was well tolerated and has been shown to be safe for up to51 months. Gastrointestinal events, mainly diarrhea, were the main adverse events caused by treatment.

The original drug of nintedanib is marketed in China as nintedanib ethanesulfonate soft capsules and is covered by Class B medical insurance, but reimbursement is limited to patients who meet the indications. SpecificationsThe price of each box of 150mg*30 capsules may be more than 4,000 yuan. Nintedanib Original drug available overseas has Turkish version and Indian version, specificationsThe price of 150mg*60 capsules per box may be more than 5,000 RMB (the price may fluctuate due to the exchange rate). There are also nintedanib generic drugs produced overseas in other countries. For example, the price of 150mg*30 capsules produced by BDR Pharmaceutical Factory in India may be several hundred yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad.